2018
DOI: 10.2298/abs170922049r
|View full text |Cite
|
Sign up to set email alerts
|

IOX-101, a novel small molecule, reduces AML cell proliferation by Akt enzyme inhibition

Abstract: Cancer of the blood continues to be a major mortality factor globally. Arylidene compounds are well known for their anticancer effects. Here we describe the biological efficacy of IOX-101, a potential lead-compound of arylidene in acute myeloid leukemia (AML). Initially, molecular docking analysis was performed to check the binding efficacy of the compound with protein kinase B (Akt). The ability of the molecule to inhibit AML proliferation was assessed in THP-1 and Kasumi-6 cells by a standard MTT assay. Hoec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 25 publications
0
3
0
Order By: Relevance
“…AML is often characterized by myeloblast-induced clonal expansion [4]. As this form of the disease has a stem cellderived hematopoietic origin, uncontrolled accumulation of these cells can be fatal [5].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…AML is often characterized by myeloblast-induced clonal expansion [4]. As this form of the disease has a stem cellderived hematopoietic origin, uncontrolled accumulation of these cells can be fatal [5].…”
Section: Introductionmentioning
confidence: 99%
“…The expression of ERs in differentiated AML cells and aberrant hematopoiesis has been assessed. In contrast, inhibitors of Akt kinase can reportedly control the proliferation of AML cells [4]. However, targeting AML cells using a dual ER and Akt inhibitor has not been evaluated.…”
Section: Introductionmentioning
confidence: 99%
“…Indane-1-ones are a class of small molecules with high drug-likeliness properties [9]. Several studies have proven Arylidene indan-1-ones to be effective against primary and resistant forms of cancers [10][11][12]. Therefore, the current investigation aims to screen one novel arylidene indanone analogue (FPMX-14) as an Akt inhibition target against renal carcinoma cells using computation and in vitro models.…”
Section: Introductionmentioning
confidence: 99%